THYSUNCT00510640
Thyroid Cancer and Sunitinib
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Study Identification, Study Status, Referencesv9
- Notable Primary completion date changed from estimate of Aug 2010 to Mar 2012
- Study completion date changed from estimate of Feb 2011 to Mar 2012
- Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 66 to confirmed 71
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 15 of 15 sites
Notable Eligibility criteria expanded, about 29 wordsv6 Show 6 more changesShow less
- Enrollment target: 75 to 66
- Primary completion date: Aug 2010
- Study completion date: Aug 2011 to Feb 2011
- Secondary endpoints: details revised at 2 of 2 entries
- Study description expanded, about 27 words
- Study sites revised (15)
- Notable Eligibility criteria revised
- Study sites: 1 to 15
Show 3 earlier versionsHide 3 earlier versions
- Notable Eligibility criteria shortened, about 1 word
- Study description shortened, about 2 words
Notable Eligibility criteria expanded, about 18 wordsv3 Show 4 more changesShow less
- Secondary endpoints revised (2)
- Study site revised
- Study description expanded, about 5 words
- Study title shortened, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective response rate (ORR) : defined as the proportion of patients with confirmed complete (CR) or partial response (PR) according to the RECIST, relative to the total patients enrolled who received at least 1 dose of trial medication
Timeframe: Every two cycles
Secondary (2)
Evaluate the safety of sunitinib in patients with thyroid carcinoma
Determine time-to-event variables of overall survival, time to: disease progression, response, and duration of response
Arms and interventions
SunitinibExperimental
Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
Drugs: Sunitinib
Sites
15 sites in 1 country